The number of chronic disease patients continues to grow, and the Internet chronic disease management market has huge potential

Chronic disease refers to the general term for diseases that do not constitute infection and have long-term accumulation of disease form damage
.
According to the "China Medium and Long-term Plan for the Prevention and Treatment of Chronic Diseases (2017-2025)", chronic diseases mainly include cardiovascular and cerebrovascular diseases, cancer, chronic respiratory diseases, diabetes and oral diseases, as well as endocrine, kidney, bone, and nerve diseases
.
In recent years, the number of patients with chronic diseases in China has been on the rise
.
The "Report on the Status of Nutrition and Chronic Diseases of Chinese Residents (2020)" shows that the prevalence of hypertension in China is 27.
5%, diabetes is 11.
9%, and hypercholesterolemia is 8.
2%, 40 The prevalence of chronic obstructive pulmonary disease among residents aged and over is 13.
6%, which has increased compared with the results released in 2015
.
The industry believes that the chronic disease drug market will have huge room for growth under the background that the main treatment for chronic diseases is long-term medication and the number of patients continues to increase
.
It is reported that in the "China Medium and Long-term Plan for the Prevention and Treatment of Chronic Diseases (2017-2025)" (hereinafter referred to as the "Plan"), the state has proposed that by 2025, chronic disease risk factors will be effectively controlled, and strive to The premature death rate caused by vascular disease, cancer, chronic respiratory disease and diabetes was reduced by 20% compared with 2015
.
In addition, with the continuous increase of chronic disease users in China, the promotion of major chronic disease prevention and control has also been included in the "Healthy China 2030" Planning Outline
.
In the context of the country's vigorous efforts to promote the prevention and treatment of chronic diseases, the continuous expansion of the chronic disease drug market has become a general trend
.
In fact, out of optimism about the market, pharmaceutical companies and Internet medical platforms are helping the prevention and treatment of chronic diseases by continuously developing chronic disease drugs and actively innovating service models
.
For example, Pfizer previously settled its headquarters in Shanghai for its non-communicable diseases (including cardiovascular and cerebrovascular diseases, pain and neurological diseases, mental diseases, urinary diseases, and ophthalmological diseases, etc.
)
.
In addition, many local pharmaceutical companies such as Yuheng Pharmaceutical and China Resources Shuanghe have also actively deployed the chronic disease field as early as two years ago, even purchasing related companies at high premiums.

.
From an overall point of view, in fact, many pharmaceutical companies have chosen to cooperate with Internet platforms in the field of chronic diseases
.
For example, on November 6, at the 4th China International Import Expo, Hanhui Pharmaceutical signed a strategic cooperation agreement with Huiyi Tianxia
.
The two parties will integrate resources to jointly explore the digital full-course management model for chronic diseases such as digestion and hyperlipidemia, and create a high-quality closed loop of out-of-hospital health management for patients with chronic diseases
.
The industry predicts that with the intensification of the aging problem and the promotion of a series of favorable policies, the management of Internet chronic diseases in the future may become a promising business opportunity in the Chinese medical market
.
It is reported that in the "White Paper on China's Internet Chronic Disease Management 2020", it pointed out that China's Internet chronic disease management has a huge market potential outside of public hospitals, and the market size is expected to exceed 230 billion yuan in 2025
.